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Background: Dementia-related neuropsychiatric symptoms (NPS) are the main determinant
of family stress and institutionalization of patients. This study aimed to identify inequalities
by gender and socioeconomic status in the management of NPS in patients diagnosed with
dementia.
Methods: An observational study was carried out to study all the cases of dementia in the
corporate database of the Basque Health Service (29,864 patients). The prescription of
antipsychotics and antidepressants and admission to a nursing home were used to establish
the presence of NPS. The socioeconomic status of individuals was classified by a deprivation
index. Logistic regressions were used to identify drivers for drug prescriptions and
institutionalization.
Results: NPS are poorly recorded in the clinical databases (12%). Neuropsychiatric symp-
toms were severe enough in two thirds of patients with dementia to be treated with
psychoactive medication. Institutionalization showed an increase from those who did not
receive medication to those who had been prescribed antidepressants (OR: 1.546), antipsy-
chotics (OR: 2.075) or both (OR: 2.741). The resulting inequalities were the increased
prescription of antidepressant drugs in women and more nursing-home admissions for
women who were the least socioeconomically deprived and men who were the most
deprived.
Conclusions: In large clinical databases, psychoactive drugs prescriptions can be useful to
underscore the considerable burden of dementia-related NPS. Specific tools are needed to
monitor social and health care programs targeted to dementia-related NPS from a population
perspective. Programs aimed at reducing the family burden of care of dementia patients at
home become the key elements in reducing inequalities in these patients’ care.
Socioeconomic status is the most important driver of inequality, and gender inequality may
simply be hidden within the social environment. Integrated programs boosting the continuity
of care are an objective for which compliance could be measured according to the NPS
coding in the electronic health record.
Keywords: neuropsychiatric symptoms, prevalence, dementia, antidepressant drugs,
antipsychotic drugs, nursing home, inequalities, deprivation index
Introduction
Dementia is more than an aggregation of symptoms that causes serious deteriora-
tion of memory, cognition and social skills; it also harms mood and behavior, which
is then expressed as distress in patients and caregivers.1 Dementia-related neurop-
sychiatric symptoms (NPS) are clinically important since they correlate strongly
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with the degree of functional damage.2,3 However, they are
relevant mainly because they are independently associated
with an increase in the economic burden and the loss of
quality of life in patients and caregivers.4 As repeatedly
reported, they are the main determinant of family giving
up to home informal care and, consequently, of institutio-
nalization of patients.1,3,5 It is estimated that up to 90% of
all patients with dementia suffer from NPS during the
course of their disease.3 Part of the negative impact of
dementia on the quality of life of patients’ relatives is
mediated by the mechanism of expressed emotion that is
significantly aggravated by the presence of NPS.6
Although the clinical research is extensive,7,8 the epi-
demiology of NPS has not been thoroughly studied
because of the lack of population registries. Also, the
scarce information that is available has been dispersed
because of separate collection by social and health
services.1,9 The available prevalence data come from
cross-sectional studies with small patient samples, and
their results vary, depending on the origin of these
investigations.1,4,10 For example, in samples recruiting
subjects with dementia living in the community, NPS are
generally less frequent and less severe than in patients
living in long-term care centers.3,5 Given the difficulties
in performing this type of study, epidemiological approx-
imations have been carried out through the analysis of the
prescription of antipsychotics.11,12 Although there are
reports of validation of dementia identification algorithms
in the clinical and administrative databases,9,13 no such
study has explored the coding of dementia-related NPS in
clinical databases.
Social determinants, such as social class, level of edu-
cation and degree of deprivation based on the area of
residence, play a key role in the health of individuals and
populations.14 Their analysis is complex because of differ-
ent ways to classify individuals socially, and the results
depend on whether the impact is evaluated by measuring
mortality, morbidity or utilization of health or social
services.15 The appearance of dementia is also related to
the unequal distribution of these determinants and to a
socially determined increase in incidence that has shown
higher rates in the groups with lower socioeconomic
levels.16 Up to the present, no study has been available
analyzing inequalities related to social factors in associa-
tion with NPS in patients with dementia. However, it is
possible that socioeconomic status and gender determine
in some way the prevalence of NPS in dementia patients
and how their care is socially managed.
This study aimed to identify inequalities by gender and
socioeconomic status in the management of neuropsychia-
tric symptoms in patients diagnosed with dementia in the
entire Basque Health Service by analyzing the use of
psychoactive medication in association with the probabil-
ity of admission to a nursing home.
Methods
An observational and cross-sectional study was carried out
to examine inequalities related to NPS based on all the
cases recorded in the corporate database of the Basque
Health Service Oracle Business Intelligence (OBI). This
database contains fully anonymous information updated
daily from administrative and clinical records of primary
care, hospitalization, emergencies and hospital outpatient
consultations. This project was approved by the Ethics
Committee of the Basque Country (PI2018087).
Subjects
The study sample included patients diagnosed with
dementia in the OBI database and alive as of December
31, 2016. The search for the diagnosis of dementia was
made by tracking validated criteria with a positive predic-
tive value of 95.1% and a negative predictive value of
99.4% 9. The searches included dementia codes (Table S1
in Supplementary Material) in ICD9-CM and ICD 10
because from January 1, 2016, it has been the official
ICD. The identification of dementia also included patients
with a specific prescription for Alzheimer’s disease.9 As
previously reported, our approach includes two thirds of
the forecasted population prevalence and therefore we
assume that the sample size is big enough to overcome
the selection bias associate to the observational design.9
Variables
Dementia cases with NPS were sought in primary care,
neurology and psychiatric consultations and hospitaliza-
tions (Table S1 in Supplementary Material). Estimating
that the coding of these diagnoses was incomplete, we
also looked within the clinical record for at least one
pharmacological treatment of mood disorders (depression,
anxiety and apathy) and psychotic disorders (aggression,
irritability, restlessness, screaming, delusions and visual
and auditory hallucinations). As private assurances in
Spain cover diagnosis and surgical treatment but not
drug treatment, prescription records also included patients
treated in private practice. To this end, the prescription of
antipsychotic medication was used as a surrogate indicator
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of the presence of psychotic-type NPS, and prescription of
antidepressant medication was an indicator of depressive
or mood-type NPS. The joint use of the two types of
prescriptions allowed the classification of patients with
dementia into four categories: without psychoactive treat-
ment (no NPS), with depressive-type NPS, with psychotic-
type NPS and with both types.
The following variables for all patients identified with
dementia were recorded: age, sex, living in a nursing
home, comorbidities (diabetes mellitus, hypertension, dys-
lipidemia, thyroid disease, Parkinson’s disease, stroke,
cardiovascular disease, head trauma, depressive disorder),
pharmacological treatment (antipsychotic medication, anti-
depressant medication) and deprivation index.
The deprivation index is an indicator of the indivi-
duals’ socioeconomic status that depends on their small
area of residence. It is defined as a state of observable and
demonstrable disadvantage in relation to the local commu-
nity to which an individual belongs16,17 and has been
adapted for the Spanish population.17 This composite
index was calculated by the Research Service of the
Health Department of the Basque Government, with the
criteria of the Mortality and Health Inequalities in Spain
(MEDEA) project based on simple indicators in the 2011
census.17 This index is divided into quintiles, with the first
(Q1) being the least disadvantaged (rich) and the fifth (Q5)
the most disadvantaged (poor). Given that social functions
help to explain the gender differences observed in health
and women systematically report poorer health than
men,16 an integrated social and gender framework has
been proposed to understand inequalities in health.14
Statistical analysis
The statistical analysis was performed in R (version 3.2.2)
in several steps. First, a univariate analysis of the charac-
teristics of the patients was carried out with Chi-square
test for the categorical variables and the variance analysis
(anova) for the comparison of means. The α statistical
significance level was set up at 0.05. Subsequently, multi-
variate logistic regression models were constructed to
analyze the probability of antipsychotic treatment, antide-
pressant treatment or both. Logistic regression was also
used to analyze the probability of residence in a nursing
home. All the logistic regression models were adjusted
according to gender, deprivation index, type of psychoac-
tive treatment and age and comorbidities. Finally, the
interactions between the variables of gender and socio-
economic deprivation were included in the four logistic
regression models. The variable that included five Q1–Q5
levels of the socioeconomic deprivation area index was re-
grouped into two categories: higher (Q1-Q3) and lower
(Q4-Q5) socioeconomic levels, to simplify the interpreta-
tion of the results. This allowed us to analyze the prob-
ability of living in a nursing home and receiving treatment
with antipsychotics, antidepressants or both in four sub-
groups (men Q1–Q3, women Q1–Q3, men Q4–Q5 and
women Q4–Q5).
Results
Of the 30,544 patients diagnosed with dementia and alive
on December 31, 2016, 680 were ruled out due to lack of a
deprivation index, so the final study sample study was
29,864. Table 1 shows their disaggregated characteristics
by type of psychoactive treatment; 69.4% were women,
and 27.6% lived in a nursing home. From the total sample,
diabetes mellitus had been diagnosed in 23.9%, traumatic
brain injury in 13.6% and stroke in 18.6%. Only one third
(33.6%) had never received either antipsychotic or anti-
depressant treatment. The rest had received antidepressant
treatment (34.0%), antipsychotic treatment (11.0%) or
both (21.5%). The percentage of patients living in a nur-
sing home was 19.8% in the untreated group, 26.8% in
those treated with antidepressants, 31.7% in those treated
with antipsychotics and 38.9% in those having been trea-
ted with both. Only 12% of patients had a record of the
code for dementia-related NPS.
The probability of individuals being treated with anti-
psychotics and antidepressants decreased with age, and
prescription of antidepressants was higher in women
(Table 2). The deprivation index behaved inconsistently,
since the probability of prescription of antidepressants was
significantly lower in groups Q3, Q4 and Q5. The group
with the highest socioeconomic status (Q1) was the most
likely to receive antipsychotic treatment, although the
differences among some groups were not statistically
significant.
When the probability of individuals being institutiona-
lized was analyzed by logistic regression (Table 3), an
increase developed from those who did not receive medi-
cation to those who had taken only antidepressants with an
odds ratio (OR) of 1.556 to those who had taken only
antipsychotics (OR, 2.075) to those who had taken both
(OR, 2.741). Women had a higher likelihood of institutio-
nalization, with a statistically significant OR of 1.286.
Also, the patients having lower socioeconomic status in
quintiles 4 and 5 were associated with a higher probability
Dovepress Mar et al
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of living in a nursing home, with statistically significant
OR of 1.131 and 1.309, respectively.
The subgroup analysis (Table 4) showed that women
from the most advantaged group (Q1–Q3) lived more
frequently in a nursing home (OR.1.27), while that char-
acteristic appeared in men at a lower socioeconomic level
(Q4–Q5) (OR, 1.12). Table 4 also shows that the only
statistically significant inequality in the use of psychoac-
tive drug was increased prescription of antidepressants in
women within the highest socioeconomic status.
Discussion
The NPS were severe enough in two thirds of all patients
living with dementia for them to have received at some
Table 1 Characteristics of patients with dementia disaggregated by psychoactive treatment type
Type of treatment




10,026 (33.6%) 10,148 (34.0%) 3,279 (11.0%) 6,411 (21.5%) 29,864 (100.0%)
Female Gender * 6,528 (65.1%) 7,452 (73.4%) 2,125 (64.8%) 4,612 (71.9%) 20,717 (69.4%)
Nursing Home * 1,988 (19.8%) 2,722 (26.8%) 1,041 (31.7%) 2,495 (38.9%) 8,246 (27.6%)
Arterial hypertension * 1,394 (13.9%) 1,877 (18.5%) 498 (15.2%) 974 (15.2%) 4,743 (15.9%)
Diabetes * 2,247 (22.4%) 2,622 (25.8%) 803 (24.5%) 1,461 (22.8%) 7,133 (23.9%)
Dyslipidemia * 1,491 (14.9%) 1,861 (18.3%) 588 (17.9%) 1,219 (19.0%) 5,159 (17.3%)
Thyroid disease * 1,252 (12.5%) 1,805 (17.8%) 475 (14.5%) 1,100 (17.2%) 4,632 (15.5%)
Parkinson’s disease * 369 (3.7%) 375 (3.7%) 232 (7.1%) 286 (4.5%) 1,262 (4.2%)
Stroke * 1,650 (16.5%) 2,118 (20.9%) 639 (19.5%) 1,158 (18.1%) 5,565 (18.6%)
Cardiovascular disease * 927 (9.2%) 1,085 (10.7%) 332 (10.1%) 624 (9.7%) 2,968 (9.9%)
Traumatic brain injury * 1,002 (10.0%) 1,520 (15.0%) 465 (14.2%) 1,084 (16.9%) 4,071 (13.6%)
Depressive disorder * 395 (3.9%) 1,478 (14.6%) 242 (7.4%) 896 (14.0%) 3,011 (10.0%)
Neuropsychiatric symptoms * 867 (8.6%) 1,377 (13.6%) 400 (12.2%) 1,119 (17.5%) 3,763 (12.6%)
Deprivation index *
Quintile 1 1,945 (19.4%) 2,033 (20.0%) 656 (20.0%) 1,389 (21.7%) 6,023 (20.2%)
Quintile 2 1,981 (19.8%) 2,100 (20.7%) 608 (18.5%) 1,315 (20.5%) 6,004 (20.1%)
Quintile 3 2,036 (20.3%) 2,087 (20.6%) 642 (19.6%) 1,154 (18.0%) 5,919 (19.8%)
Quintile 4 2,070 (20.6%) 1,979 (19.5%) 691 (21.1%) 1,325 (20.7%) 6,065 (20.3%)
Quintile 5 1,994 (19.9%) 1,949 (19.2.0%) 682 (20.8%) 1,228 (19.2%) 5,853 (19.6%)
Age mean (SD) 84.18 (9.59) 83.96 (8.10) 83.54 (6.62) 83.48 (6.65) 83.88 (8.22)
Notes: Quintile 1: least deprived; Quintile 5: most deprived. *Existence of statistically significant differences at α=0.05.
Abbreviation: SD, standard deviation.
Table 2 Logistic regressions analyzing the probability of patients being treated with antidepressants, antipsychotics or both
Antidepressants Antipsychotics Antipsychotics and Antidepressants
OR OR OR
(Intercept) 1.384 ** 0.934 NS 0.488 ***
Time with dementia (Continuous) 0.993 * 0.995 NS 1.027 ***
Age (Continuous) 0.994 *** 0.992 *** 0.991 ***
Gender (Female) 1.399 *** 1.018 NS 1.128 ***
Deprivation index (Quintile 2) 0.982 NS 0.913 * 0.929 NS
Deprivation index (Quintile 3) 0.902 ** 0.847 *** 0.804 ***
Deprivation index (Quintile 4) 0.894 ** 0.968 NS 0.932 NS
Deprivation index (Quintile 5) 0.855 *** 0.929 NS 0.864 **
Notes: Adjusted by diagnosis of arterial hypertension, diabetes mellitus, dyslipidemia, thyroid disease, Parkinson’s disease, stroke, cardiovascular disease and traumatic brain
injury. Statistical Significance codes: P<0.001 “***”; P<0.01 “**”; P≤0.05 “*”. Quintile 1: least deprived; Quintile 5: most deprived.
Abbreviations: OR, odds ratio; NS, not significant.
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time a prescription for psychoactive medication (antide-
pressants and/or antipsychotics). The inequalities that we
found in prescription for psychoactive drugs and nursing-
home admissions were related more to gender than to
socioeconomic status. The strength of the study is its
population approach that includes in the sample the entire
population of cases of declared dementia. The Basque
Health Service is a tax-funded Beveridge-type system
and covers a population of 2.2 million inhabitants. The
registered dementia cases included two thirds of the cases
that would be expected according to the prevalence indi-
cated by Ferri et al for the European countries, which
indicates a high level of identification.9,18 However, the
12% registration of the NPS indicates a low explicit recog-
nition of the problem, despite the fact that evidence shows
that the prescription of antipsychotics and antidepressants
is one of the biggest clinical challenges in dementia care.19
The figures in our analysis for prescription of antipsycho-
tic (33%) and antidepressant (55%) treatment in dementia
cases are similar to those described in other studies and
correspond to a mixture of the population living in the
community and in institutions.10 Olfson et al described
higher figures in the American population more than
75 years of age with a diagnosis of dementia (37% for
75–79 years of age and 48% for 80–84 years).11 The
finding that 27% of dementia patients are institutionalized
is close to the 33% described in the United Kingdom.20
Although the use of antipsychotics did not show differ-
ences by gender, our results showed an inequality in anti-
depressant treatment, since these drugs were prescribed
more often for women in all the statistical models. In study-
ing differences in the NPS of male and female patients with
Alzheimer’s disease in a clinical sample, Tao et al con-
cluded that women displayed greater heterogeneity in the
presentation of NPS, but no significant differences in the
number.21 In our study, there were no consistent differences
when patients were classified according to their socioeco-
nomic status measured by the deprivation index. Although
in the initial analysis with five quintiles, the patients in
group Q1 (least deprived) received more prescriptions of
antipsychotics, the results were not statistically significant
in the analysis of subgroups.
Table 3 Logistic regression analyzing the probability that patients
were living in a nursing home
OR Std.
Error
(Intercept) 0.005 0.169 ***
No psychoactive treatment (reference) -
Type of treatment (Antidepressants) 1.556 0.035 ***
Type of treatment (Antipsychotics) 2.075 0.046 ***
Type of treatment (Antidepressants and
Antipsychotics)
2.741 0.037 ***
Age 1.040 0.002 ***
Gender (Female) 1.286 0.032 ***
Arterial hypertension 0.970 0.038 NS
Diabetes 1.082 0.032 *
Dyslipidemia 1.012 0.036 NS
Thyroid disease 0.866 0.038 ***
Parkinson’s disease 1.116 0.066 NS
Stroke 1.155 0.034 ***
Cardiovascular disease 0.939 0.046 NS
Traumatic brain injury 1.472 0.037 ***
Depressive disorder (Yes) 0.881 0.045 **
Deprivation index (Quintile 2) 1.087 0.043 NS
Deprivation index (Quintile 3) 1.085 0.043 NS
Deprivation index (Quintile 4) 1.131 0.042 **
Deprivation index (Quintile 5) 1.309 0.0424 ***
Notes: Statistical Significance codes: P<0.001 “***”; P<0.01 “**”; P≤0.05 “*”.
Quintile 1: least deprived; Quintile 5: most deprived.
Abbreviations: OR, odds ratio; NS, not significant.
Table 4 Logistic regression models including gender and deprivation index interactions (subgroup analysis) analyzing the probability of









OR OR OR OR
Gender (Male) # Deprivation index Q1-Q3 1 1 1 1
Gender (Female) # Deprivation index Q1-Q3 1.27* 1.43* 0.99 1.11*
Gender (Male) # Deprivation index Q4-Q5 1.12* 0.95 0.99 0.96
Gender (Female) # Deprivation index Q4-Q5 1.03 0.94 1.07 1.04
(Intercept) 0.01* 1.31* 0.87 0.45*
Notes: *Interaction statistically significant (p<0.05). Adjusted by age, diagnosis of arterial hypertension, diabetes mellitus, dyslipidemia, thyroid disease, Parkinson’s disease,
stroke, cardiovascular disease and traumatic brain injury. Quintile 1: least deprived; Quintile 5: most deprived. #Interaction between two variables.
Abbreviation: OR, odds ratio.
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According to the model without interactions, which
focused on estimating the probability of institutionalization,
women and the most deprived groups (Q4, Q5) had a higher
risk of living in nursing home. However, when the interac-
tions were incorporated into the analysis, only women with
the most advantaged deprivation index (Q1-Q3) were more
likely to live in institutions, whereas that characteristic
appeared in men with the lowest socioeconomic status
(Q4-Q5). The demand for institutionalization arises when
the needs of patients and their caregivers are not solved due
to the severity of symptoms and the lack of resources at
home.22 Despite the development of the Dependency Law
in Spain that has boosted social services, most of the care
for patients with dementia is delivered by informal care-
givers at home.23,24
The finding of more antidepressant prescriptions in
women could indicate that they present with more NPS,
which determines a more likely institutionalization.4,5
However, we found an inverse association between socio-
economic status and gender in the risk of institutionaliza-
tion that may be due to the different social roles of women
and men in relation to home care. Men at the highest
socioeconomic levels (Q1–Q3) can stay at home because
they have economic resources. Moreover, as they are more
frequently married, their spouses often become the
caregivers.25 When the woman is the dependent one,
even with the financial resources available, the social
environment is less prone to adapt to allow her to stay at
home. Consequently, “rich” women may move to nursing
homes because they do not receive adequate support at
home. If the civil status of the cases had been available,
we could have taken into account the percentage of
widowed men. In the subgroup of most socioeconomically
deprived men (Q4–Q5), their families may have fewer
resources to maintain them adequately at home, and social
services may have to take responsibility for their admit-
tance to a nursing home.4 We do not have a clear explana-
tion for the lower risk of institutionalization of women in
groups Q4-Q5, when compared to men in the same groups.
Non-pharmacological treatments are the first choice for
the treatment of dementia-related NPS in most of the clin-
ical guidelines.12,26 Despite this, pharmacological treatment
is the most used.11 In Spain, as in many other countries,
environmental and behavioral treatments are not easily
accessible. Making those programs available would help
to reduce the number of prescriptions for antipsychotics,
which has been recommended as a goal in dementia policy
documents in the United Kingdom and United States.11,12
Different official reports have proposed limiting antipsy-
chotic medication in patients with NPS, underlining the
need to take into account, in all cases, the risk-benefit
balance.20,26–28 After these warnings, the use of antipsycho-
tics in the UK has decreased from 22.1% in 2005 to 11.4%
in 2015, and from 2001 to 2014 the prescription of first-
generation antipsychotics was greatly reduced.29
Conversely, the use of the new antipsychotics underwent
few changes.12 In the region of Valencia (Spain) olanzapine
and risperidone prescriptions were reduced after a safety
warning was instituted.28 The goal of adequate use of psy-
choactive drugs based on the risk-benefit profile is to help
patients and families cope with the stress caused by demen-
tia-related NPS. The finding of a statistically significant rise
in the risk of institutionalization highlights the meaning of
the prescription of psychoactive drugs by confirming at the
population level the determinant weight of NPS in family
giving up to home informal care and nursing home admis-
sion that has already been displayed in clinical samples.1,10
The strong discordance between drug prescription and the
percentage of patients formally diagnosed with NPS rein-
forces the need for a thorough understanding of these indi-
cators. The existence of an increase in nursing-home
admissions associated with the prescription of antidepres-
sants and antipsychotics fits well with higher family distress
related to psychotic or behavior disorders.30,31
The use of prescriptions as a surrogate indicator of the
presence of NPS in patients with dementia is hampered by
the existence of other indications and the inappropriate use
of such prescriptions.11,12,26 Specific instruments such as
the Neuropsychiatric Inventory (NPI) 7 or Behavioral
Pathology in Alzheimer’s Disease (BEHAVE-AD)8
would be more valid to measure the presence of NPS,
but their use in large clinical databases is not feasible for
now. But, as the Organisation for Economic Co-operation
and Development has remarked, a big data approach offers
new tools to identify in clinical databases (broad data)
patterns in cases of dementia requiring specific care.32
The term NPS is conceptually related to challenging
behavior30 since these symptoms pose situations that can-
not be managed in their environment without resorting to
pharmacological treatment. Therefore, in the context of the
natural history of dementia characterized by a progression
in time, it seems reasonable to use psychoactive medica-
tion as a milestone that indicates that, beyond the physical
functioning of the patient, NPS present a severe problem
that requires intensive social care.33 Although NPS can
affect 95% of patients with dementia at some point in the
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evolution of the disease, the number of those who require
the prescription of antipsychotics and antidepressants at a
given moment indicates the group that has exceeded the
threshold in the level of distress that caregivers can
endure.31 The percentage of pharmacologically treated
patients seems to be a more useful indicator than the
12% of cases with a registered NPS diagnosis that we
found.
Conclusions
The aim of our study was not to analyze the correct use of
psychoactive medication, but to examine whether the ana-
lysis of its prescription in population-based databases can
help lead to a clearer understanding of the burden of NPS
in dementia patients. In a vicious cycle, this burden is
underestimated because it is not recorded, and conse-
quently, no efforts are made to measure it because the
symptoms are not considered relevant. The scant attention
observed in the population registries may also be a reflec-
tion of a fatalistic approach in which it is understood that
NPS are unavoidable and have no effective treatment. To
break this vicious cycle, specific tools are needed to moni-
tor social and health care programs targeted to dementia-
related NPS from a population perspective. Integrated
programs boosting the continuity of care in the follow-up
by social workers, primary care physicians and nurses,
neurologists and psychiatrists are an objective for which
compliance could be measured according to the coding in
the electronic health record. Big data offers new tools to
identify patterns associated with NPS in dementia
patients.32
Access to nursing homes generally is going to be a
problem for most deprived people. Moreover, the eco-
nomic barrier for patients with NPS will expand for two
reasons. First, neuropsychiatric patients require more
resources, thereby increasing the cost to nursing homes.
Second, aging populations foreshadow growing needs.
Thus, programs aimed at reducing the family burden of
care of dementia patients at home become the key ele-
ments in reducing inequalities in these patients’ care.
Socioeconomic status is the most important driver of
inequality, and gender inequality may simply be hidden
within the social environment.
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